A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design

by Chen Y, Vaine M, Kong X, Montefiori D, Wang S, Lu S
Published 2012-09-01

P03-10. Induction of neutralizing antibodies in Rhesus macaques following mucosal challenge with R5 tropic SHIV162P3 isolate

by Montefiori D, Finke L, Weiss D, Suschak J, Galmin L, Chung H, PAL R
Published 2009-10-01

Characterization in rabbits & nonhuman primates of the neutralizing antibody response elicited by DNA & protein vaccination with SIVmac251 & SIVsmE660

by Menon VP, Whitney S, Francis J, Ajayi L, Petrovsky N, Montefiori D, Pal R, Vaniambadi K
Published 2012-09-01

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER

by Han D, Habte H, Qin Y, Takamoto K, LaBranche C, Montefiori D, Cho MW
Published 2012-09-01

Priming with DNA encoding functional trimers and boosting with soluble trimeric protein elicited tier 2 neutralizing antibodies in non-human primates

by Chakrabarti BK, Yu F, McKee K, Labranche C, Montefiori D, Mascola JR, Wyatt RT
Published 2012-09-01

Vaccine-elicited systemic and mucosal humoral responses of lactating rhesus monkeys vaccinated with the transmitted/founder HIV Envelope 1086C

by Fouda G, Amos J, Wilks AB, Chand A, Montefiori D, Haynes B, Letvin N, Pickup D, Liao H, Permar SR
Published 2012-09-01

Rationally designed HIV envelope glycoproteins delivered in a novel adjuvant elicited more broadly reactive antigen-specific antibody responses

by Dey AK, Kassa A, Nandi A, Sun Y, Labranche C, Hartog K, Montefiori D, Carfi A, Srivastava I, Barnett SW
Published 2012-09-01

P05-12. A computationally designed immunogen elicits potent anti-V3 neutralizing antibodies

by Stamatatos L, Strong R, Montefiori D, Kalyuzhniy O, Ellingson K, Bretz C, Ban YA, Boni E, Lagerquist E, Carrico CT, Schief W
Published 2009-10-01

E-DNA IM or ID delivery prime enhances antibody and T cell responses following recombinant gp120 env boost

by Hutnick NA, Karuppiah M, Pollara J, Yan J, Myles DJ, Broderick K, Morrow M, Sardasai N, Montefiori D, Barnett S, Ferrari G, Weiner DB
Published 2012-09-01

P04-11. Prevalence of neutralizing antibody responses in chronic clades A and D human immunodeficiency virus type 1 (HIV-1) infections

by Grosskurth H, Kamali A, Maher D, Levin J, Vanham G, Balla S, Montefiori D, Sokolik-Wolak B, Tomusange K, Njai HF, Pala P, Kaleebu P
Published 2009-10-01

P04-12. Characterization of leukopak PBMC phenotypes and biotypes for optimal performance in HIV-1 neutralization assays

by Montefiori D, Michael NL, Ochsenbauer-Jambor C, Kappes JC, Kijak G, Wieczorek L, Thelian D, Currier J, Bryson M, Lombardi K, Brown BK, Polonis VR
Published 2009-10-01

Targeting HIV-1 envelope glycoprotein trimers to B cells using APRIL improves antibody responses

by Melchers M, Bontjer I, Tong T, Chung N, Klasse P, Eggink D, Gentile M, Cerutti A, Montefiori D, Olson W, Berkhout B, Binley J, Moore J, Sanders R
Published 2012-09-01

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting

by Spearman P, Tomaras G, Montefiori D, Huang Y, Ahmed H, Elizaga M, Hural J, McElrath J, Ouedraogo L, Pensiero M, Butler C, Kalams S, Overton ET, Barnett S, Group N
Published 2012-09-01

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles

by Goepfert P, Elizaga M, Montefiori D, Hural J, DeRosa S, Tomaras G, Seaton K, Sato A, Ouedraogo L, Donastorg Y, Cardinali M, Lama J, Baden L, Keefer M, McElrath J, Kalams S, Robinson H
Published 2012-09-01

P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group

by Polonis V, Osmanov S, Morris L, Moog C, Montefiori D, Malnati M, Lopalco L, Jansson M, Holmes H, Heyndrickx L, Heath A, Fenyö E, Bongertz V, Alcami J, Scarlatti G, Ramaswamy M, Sattentau Q, Schuitemaker H, Wrin T
Published 2009-10-01

P04-28. Breadth and magnitude of neutralizing antibody responses in subjects infected with HIV-1 subtype D or recombinants in Rakai district, Uganda

by Robb ML, Michael NL, Gray R, Wawer M, Sewankambo N, Serwadda D, Kiwanuka N, Quinn T, Laeyendecker O, Wabwire-Mangen F, de Souza MS, Eller MA, Oballah P, Ouma B, Eller L, Montefiori D, Brown BK, Polonis VR
Published 2009-10-01

Identification of a clade A HIV envelope immunogen from Protocol G that elicits neutralizing antibodies to tier 2 viruses

by Hoffenberg S, Pond S, Carpov A, Wagner D, Wilson A, Powell R, Lindsay R, Arendt H, DeStefano J, Poignard P, Simek M, Fling S, Phogat S, Labranche C, Montefiori D, Burton D, Parks C, King C, Koff W, Caulfield M
Published 2012-09-01

Postnatally-transmitted HIV-1 variants are efficient at dendritic cell trans-infection and sensitive to autologous and heterologous neutralization

by Fouda GG, Mahlokozera T, Rizzolo K, Salazar-Gonzalez J, Salazar M, Learn G, Barotra S, Sekaran M, Russell E, Jaeger F, Cai F, Gao F, Hahn B, Swanstrom R, Meshnick S, Mwapasa V, Kalilani L, Fiscus S, Montefiori D, Haynes B, Kwiek J, Alam M, Permar S
Published 2012-09-01

Vaccine-induced ADCC-mediating antibodies target unique and overlapping envelope epitopes

by Pollara J, Bonsignori M, Moody M, Alam M, Liao H, Hwang K, Pickeral J, Kappes J, Ochsenbauer C, Soderberg K, Gurley TC, Kozink DM, Marshall DJ, Whitesides JF, Montefiori D, Robinson JE, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Kim J, Michael N, Tomaras G, Haynes BF, Ferrari G
Published 2012-09-01